JP2023505318A5 - - Google Patents
Info
- Publication number
- JP2023505318A5 JP2023505318A5 JP2022534370A JP2022534370A JP2023505318A5 JP 2023505318 A5 JP2023505318 A5 JP 2023505318A5 JP 2022534370 A JP2022534370 A JP 2022534370A JP 2022534370 A JP2022534370 A JP 2022534370A JP 2023505318 A5 JP2023505318 A5 JP 2023505318A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- domain
- antibodies
- derived
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214104.2 | 2019-12-06 | ||
| EP19214104 | 2019-12-06 | ||
| PCT/EP2020/084831 WO2021111003A1 (en) | 2019-12-06 | 2020-12-07 | Humanized cldn18.2 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505318A JP2023505318A (ja) | 2023-02-08 |
| JP2023505318A5 true JP2023505318A5 (enExample) | 2023-10-24 |
| JP7641967B2 JP7641967B2 (ja) | 2025-03-07 |
Family
ID=68808161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534370A Active JP7641967B2 (ja) | 2019-12-06 | 2020-12-07 | ヒト化ｃｌｄｎ１８．２抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230030674A1 (enExample) |
| EP (1) | EP4069738A1 (enExample) |
| JP (1) | JP7641967B2 (enExample) |
| KR (1) | KR20220111308A (enExample) |
| CN (1) | CN114901696B (enExample) |
| AU (1) | AU2020398045A1 (enExample) |
| CA (1) | CA3159465A1 (enExample) |
| WO (1) | WO2021111003A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202241519A (zh) * | 2020-12-23 | 2022-11-01 | 捷克商舒迪安生物技術公司 | 腫瘤特異性密連蛋白１８﹒２抗體藥物結合物 |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| CN117295524A (zh) | 2021-06-02 | 2023-12-26 | 百奥泰生物制药股份有限公司 | 药物偶联物及其用途 |
| WO2022266219A1 (en) * | 2021-06-15 | 2022-12-22 | Xencor, Inc. | Heterodimeric antibodies that bind claudin18.2 and cd3 |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| WO2025077829A1 (zh) * | 2023-10-13 | 2025-04-17 | 信达细胞制药(苏州)有限公司 | Cldn18.2抗体及car-t细胞在治疗cldn18.2阳性实体瘤中的应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2343001A1 (en) | 1998-09-16 | 2000-03-23 | Zymogenetics, Inc. | Stomach polypeptide zsig28 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| JP6499079B2 (ja) | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | クローディンを発現するガン疾患を処置するための剤 |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014145444A1 (en) * | 2013-03-15 | 2014-09-18 | Pilltek Llc | Systems, methods, and apparatuses for securely dispensing one or more prescribed substances to a securely identified intended user |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| ES2979068T3 (es) | 2016-07-08 | 2024-09-24 | Crage Medical Co Ltd | Anticuerpos para anti-claudina 18A2 y utilización de los mismos |
| CN109970857B (zh) * | 2017-12-27 | 2022-09-30 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| SG11202007055QA (en) * | 2018-03-08 | 2020-09-29 | Phanes Therapeutics Inc | Anti-claudin 18.2 antibodies and uses thereof |
| WO2019175617A1 (en) | 2018-03-10 | 2019-09-19 | Pratik Sharma | Data redundancy and elimination module |
| US11059887B2 (en) | 2018-05-18 | 2021-07-13 | Lanova Medicines Limited Company | Anti-claudin 18.2 antibodies and uses thereof |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| WO2021130291A1 (en) * | 2019-12-23 | 2021-07-01 | SOTIO a.s. | Tumor-specific claudin 18.2 antibodies |
| TW202241519A (zh) * | 2020-12-23 | 2022-11-01 | 捷克商舒迪安生物技術公司 | 腫瘤特異性密連蛋白１８﹒２抗體藥物結合物 |
| WO2022268983A2 (en) * | 2021-06-23 | 2022-12-29 | Cytune Pharma | Interleukin-15 based immunocytokines |
| KR20240043797A (ko) * | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| US12614475B2 (en) * | 2023-09-06 | 2026-04-28 | Ford Global Technologies, Llc | Systems and methods for facilitating touring in a vehicle |
-
2020
- 2020-12-07 US US17/782,417 patent/US20230030674A1/en active Pending
- 2020-12-07 EP EP20816527.4A patent/EP4069738A1/en active Pending
- 2020-12-07 WO PCT/EP2020/084831 patent/WO2021111003A1/en not_active Ceased
- 2020-12-07 JP JP2022534370A patent/JP7641967B2/ja active Active
- 2020-12-07 CN CN202080091553.6A patent/CN114901696B/zh active Active
- 2020-12-07 AU AU2020398045A patent/AU2020398045A1/en active Pending
- 2020-12-07 KR KR1020227022671A patent/KR20220111308A/ko active Pending
- 2020-12-07 CA CA3159465A patent/CA3159465A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023505318A5 (enExample) | ||
| JP7651031B2 (ja) | Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法 | |
| US10494446B2 (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
| Krah et al. | Engineering bispecific antibodies with defined chain pairing | |
| Labrijn et al. | When binding is enough: nonactivating antibody formats | |
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP2025142045A5 (enExample) | ||
| Caravella et al. | Design of next-generation protein therapeutics | |
| JP7822587B2 (ja) | ヘテロ二量体化Ｉｇドメイン | |
| JP2022537931A5 (enExample) | ||
| JP2016514676A (ja) | 四価二重特異性抗体 | |
| CN109796532B (zh) | 靶向成纤维激活蛋白α的结合单元及其应用 | |
| JP2024532482A5 (enExample) | ||
| CA3079363A1 (en) | Multispecific antigen binding proteins | |
| US20180371088A1 (en) | TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY | |
| US20200354457A1 (en) | Bispecific antibodies comprising an antigen-binding site binding to lag3 | |
| JP2024515301A5 (enExample) | ||
| US20250243274A1 (en) | Compositions for Redirecting Immunoglobulins to Immune Cells | |
| JP2021519589A5 (enExample) |